Outcomes
pulmonary embolism, stroke, bleeding
PULMONARY EMBOLISM, ACUTE MYOCARDIAL INFARCTION, BLEEDING, THROMBOEMBOLIC EVENT, DEEP VEIN THROMBOSIS (DVT), ADVERSE EVENTS, STROKE, COMPLICATIONS
Primary outcome was the rate of adverse events (AEs) in particular bleeding complications during treatment, at the end of treatment (EOT) and at 30 days after EOT, and occurrence of thromboembolic event at 90 days after COVID-19 diagnosis. Symptomatic thromboembolic events were objectively confirmed deep vein thrombosis (DVT with compression ultrasound), pulmonary embolism (PE with CT pulmonary angiography), stroke (with CT scan), acute myocardial infarction (according to the 4